Colossal Biosciences is reportedly raising at a $20B–$30B valuation

Signals Inbox·July 20, 2026·Synthetic Biology

Colossal Biosciences is reportedly discussing a new funding round at a $20 billion to $30 billion valuation. That would roughly double or triple its early-2025 price before it delivers a mammoth or dodo, suggesting investors are now betting on the biotech platform hiding behind the de-extinction headlines.

Q1What actually happened?

Axios originally reported that Colossal is discussing a new raise at a valuation between $20 billion and $30 billion. The company has not announced a closed round, its size, or a lead investor. The talks have reportedly been running for months and may be nearing a decision.

Q2How big is that jump?

Very big. Colossal was valued at $10.2 billion after raising $200 million in January 2025. An extension later lifted that figure slightly to $10.3 billion. The new range would put it at roughly two to three times that value in about 16 months. It was reportedly worth only $1.5 billion in 2023.

Q3Has Colossal actually revived an extinct animal?

Not in the clean Jurassic Park sense. Colossal created genetically edited gray wolves with selected dire-wolf-like traits, but scientists have challenged the idea that these are truly resurrected dire wolves. Its mammoth target remains 2028, while its dodo timeline is still five to seven years. The valuation is running far ahead of the flagship products.

Q4So what are investors really buying?

Probably the technology built along the way. Colossal works on gene editing, reproductive biology, artificial wombs, genomic software and conservation tools. It has also produced spinouts including Form Bio and Breaking. Another related predictive-biology company, Astromech, reportedly reached a $2 billion valuation. The extinct animals attract attention, but the reusable biotech may hold the value.

Q5What changed since the last valuation?

The biggest change is revenue. Colossal was pre-revenue during its previous major round, but sources now say it has started making some money. It also received $60 million through a UAE partnership, expanded government work and added more conservation programs. The problem is that its revenue level and margins remain undisclosed.

Q6What is the real point of tension?

Colossal could become a $30 billion company before proving its most famous promise. That means investors are either seeing a powerful synthetic-biology platform early, or paying a huge premium for future businesses that barely exist today. The round matters because it will show whether private markets now treat ambitious biology platforms like frontier AI companies.

Q7What should we watch next?

First, whether the round actually closes and at which end of the range. Then watch the amount raised, the lead investor and any revenue disclosure. Scientifically, the key tests are the 2028 mammoth target, the artificial-womb timeline and whether Colossal’s conservation tools produce repeatable government or commercial contracts. The valuation is impressive, but execution now has to catch up.